The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development ...

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

and an estimated one million individuals with an inherited degenerative nerve condition called Charcot–Marie–Tooth disease type 2 (CMT2). Peripheral neuropathy can cause severe disability and ...

The Grammy-winning musician went public about living — and performing — with a neurological condition called Charcot-Marie-Tooth disease in 2021, about a decade after being diagnosed.

dysfunction is an underappreciated disease characteristic in patients with Charcot-Marie-Tooth disease (CMT) types 1 and 2 affecting muscle function in patients Additionally, results from ...

a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial. The company has insisted, however, that it may still be able to make a case for the PXT3003 ...

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd ...

US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...

Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B.